Podcast appearances and mentions of Erin D Michos

In this CCO Nephrology podcast episode, hear from cardiologist Erin D. Michos, MD, MHS, FACC, FAHA, FASE, FASPC, and nephrologist Mark J. Sarnak, MD, MS, as they discuss new and emerging therapies designed to target residual inflammatory risk associated with ASCVD and CKD.    Episode outline:   Colchicine: inhibition of NLRP3 inflammasome assembly/activationCanakinumab (anti–IL-1β monoclonal antibody)Ziltivekimab (anti–IL-6 monoclonal antibody)Other emerging targets/therapies To learn more about targeting residual risk associated with systemic inflammation, find more educational activities and resources with the links below:   CME-certified text module with animated pathophysiology video and faculty voice audio clips ClinicalThought commentaries Podcast episode 1, discussing residual risk associated with systemic inflammation and the role of cardiologists and nephrologists in mitigating risk in ASCVD and CKD Podcast episode 2, discussing novel therapeutic approaches to address residual inflammatory risks in patients with ASCVD and CKD 

In this CCO Nephrology podcast episode, hear from cardiologist Erin D. Michos, MD, MHS, FACC, FAHA, FASE, FASPC, and nephrologist Mark J. Sarnak, MD, MS, as they explore new and emerging strategies to target residual risk associated with systemic inflammation in patients with ASCVD and CKD.    Episode outline:   The relationship among systemic inflammation, ASCVD, and CKD The role of cardiologists and nephrologists in screening and mitigating systemic inflammation To learn more about targeting residual risk associated with systemic inflammation, find more educational activities and resources with the links below:   CME-certified text module with animated pathophysiology video and faculty voice audio clips ClinicalThought commentaries Podcast episode 2, discussing novel therapeutic approaches to address residual inflammatory risks in patients with ASCVD and CKD Podcast episode 3, featuring faculty discussion of new and emerging therapies to target inflammatory risk in patients with ASCVD and CKD 

In this CCO Nephrology podcast episode, hear from cardiologist Erin D. Michos, MD, MHS, FACC, FAHA, FASE, FASPC, and nephrologist Mark J. Sarnak, MD, MS, as they explore the pathophysiology and novel therapeutic strategies to target residual inflammatory risk associated with ASCVD and CKD.    Episode outline:   Moving beyond lipid lowering to address residual inflammatory riskNovel anti-inflammatory targets for ASCVD To learn more about targeting residual risk associated with systemic inflammation, find more educational activities and resources with the links below:   CME-certified text module with animated pathophysiology video and faculty voice audio clipsClinicalThought commentariesPodcast episode 1, discussing residual risk associated with systemic inflammation and the role of cardiologists and nephrologists in mitigating risk in ASCVD and CKD Podcast episode 3, featuring faculty discussion of new and emerging therapies to target inflammatory risk in patients with ASCVD and CKD 

Interview with Erin D. Michos, MD, MHS, and Salman Zahid, MD, authors of Analysis of Cardiovascular Complications During Delivery Admissions Among Patients With Systemic Lupus Erythematosus, 2004-2019. Hosted by Angel N. Desai, MD, MPH. Related Content: Analysis of Cardiovascular Complications During Delivery Admissions Among Patients With Systemic Lupus Erythematosus, 2004-2019

This week we bring you a sample of the CardioNutrition program airing on ACC's CardiaCast podcast. Enjoy! The recent prevention guideline from the American College of Cardiology recommends that all adults should consume a healthy diet that emphasizes the intake of vegetables, fruits, nuts, whole grains, lean vegetable or animal protein, and fish and minimizes the intake of trans fats, processed meats, refined carbohydrates, and sweetened beverages. Counseling and caloric restriction are recommended for achieving and maintaining weight loss in the overweight or obese. In this episode, Erin D. Michos, MD, MHS, FACC, FAHA, FASE, FASPC and Robert J. Ostfeld, MD, MSc, FACC discuss a Mediterranean Dietary Pattern. Key Takeaways: A Mediterranean dietary pattern includes vegetable, fruits, legumes, whole grains, fish, lean animal proteins and limits highly processed foods. Compared to a more typical Western dietary pattern, a Mediterranean dietary pattern is associated with improved cardiovascular outcomes

Credits: 0.25 AMA PRA Category 1 Credit™ CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/influenza-populations-at-high-risk-3 Overview: Join us to discover why it is important to prevent influenza and treat patients with influenza who have cardiometabolic disease. After this brief podcast, you will be able to identify the types of cardiovascular and metabolic diseases that put patients at high risk of influenza complications and determine which patients should get the high-dose influenza vaccine, according to recent data. You will also be able to answer the question of whether anti-influenza drugs affect the risk of incident cardiovascular events. Find out all this and more to protect your patients with cardiometabolic disease this influenza season. Hosts: Erin D. Michos, MD, MHS, FACC, FAHA, FASE, FASPC; Charles Vega, MD, FAAFP Executive Producer: Margaret Oliverio, MD

Guest: Erin D. Michos, MD, MHS, FACC, FAHA, FASE Join Dr. Erin Michos, an Associate Professor of Medicine and Director of Women’s Cardiovascular Health and the Associate Director of Preventive Cardiology at Johns Hopkins Medicine in Odenton, Maryland, as she briefly discusses evolving interprofessional care models in type 2 diabetes management for patients at risk of cardiovascular disease.

CME credits: 0.50 Valid until: 26-05-2022 Claim your CME credit at https://reachmd.com/programs/cme/should-epa-be-another-e-abcs-cvd-risk-prevention-straight-talk-experts/12348/ This activity is presented by outstanding educators in the field of lipidology and preventive cardiology. Join Drs. Erin D. Michos, James A. Underberg, and Nathan D. Wong for a deep dive into these hot topics: new pathways to manage high risk in ASCVD, differential biological effects of omega-3 fatty acids, and practical considerations to manage ASCVD risk.

CME credits: 0.50 Valid until: 26-05-2022 Claim your CME credit at https://reachmd.com/programs/cme/should-epa-be-another-e-abcs-cvd-risk-prevention-straight-talk-experts/12348/ This activity is presented by outstanding educators in the field of lipidology and preventive cardiology. Join Drs. Erin D. Michos, James A. Underberg, and Nathan D. Wong for a deep dive into these hot topics: new pathways to manage high risk in ASCVD, differential biological effects of omega-3 fatty acids, and practical considerations to manage ASCVD risk.

Host: Eliot Brinton, MD, FAHA, FNLA Guest: Erin D. Michos, MD, MHS, FACC, FAHA, FASE The latest information and guideline updates that healthcare professionals need to know for their practice are included in the recent AHA/ACC/Multisociety Blood Cholesterol Guidelines. These guidelines also introduce female-specific risk enhancers to help assess cardiovascular risk in women and discuss several new options for lowering LDL-C. Also examined is the new treatment option available for those with elevated triglyceride levels at risk of ASCVD events. The results from the REDUCE-IT trial on icosapent ethyl have led to new FDA indications and updates to many guidelines that now incorporate its use for patients with a high risk of a serious event and an elevated triglyceride level. The key takeaway from this expert dialogue is that lipid management has been redefined.

In this podcast, Erin D. Michos, MD, MHS, from Johns Hopkins University, answers our questions about her team's latest study on women who are training in cardiology, how women are represented in cardiology and its subspecialties, and more. More at: www.consultant360.com/cardiology